BioCryst Pharmaceuticals | BCRX - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Chugai Pharma JPY 169.02B 8.83B 2026-06
Daiichi Sankyo JPY -6.52B 113.25B 2026-03
DBV Technologies USD -47.4M 14.24M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novavax USD 17.9M 220.94M 2025-12
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06